USFDA pulls up Mylan for manufacturing violations at Andhra plant

In a warning letter issued to the company's CEO Heather Bresch, the US Food and Drug Administration (USFDA) said inspectors during May 27 to June 5, this year found significant deviations from standard manufacturing practices at the company's Unit 8 in G Chodavaram village in Vizianagaram.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35beZx1
via IFTTT